Daily Cosmetic Research Analysis
Analyzed 17 papers and selected 3 impactful papers.
Summary
Across cosmetic and reconstructive dermatologic surgery, two randomized trials report improved early healing and scarring outcomes with adjuncts or novel materials, while a methodological paper introduces a rapid in vivo metric to quantify blue-light protection. Collectively, these studies advance perioperative care and standardization of cosmetic product evaluation.
Research Themes
- Adjunctive therapies to accelerate postoperative wound healing
- Novel biomaterials and suture strategies for improved cosmetic outcomes
- Methodological standardization for visible-light protection assessment
Selected Articles
1. Investigation of oral bromelain supplementation on the healing of skin flap reconstruction after Mohs micrographic surgery (MMS) for non-melanoma skin cancers (NMSCs).
In a single-center, single-blinded RCT (n=60), oral bromelain (1500 mg/day for 15 days) after MMS flap reconstruction accelerated healing by shortening time to suture removal by 2.6 days and improved early wound healing scores, with no reported adverse effects. Findings support bromelain as a safe adjunct in reconstructive skin cancer surgery.
Impact: Provides randomized, registered clinical evidence for a low-risk, orally administered adjunct that measurably accelerates postoperative healing after MMS.
Clinical Implications: Consider bromelain as an adjunct after MMS flap reconstruction to modestly shorten time to suture removal and improve early healing, while integrating patient-specific risk assessment and monitoring.
Key Findings
- Single-blinded RCT (n=60) showed bromelain shortened time to suture removal by 2.6 days versus control.
- Early Wound Healing Score improved with bromelain compared to standard care.
- No adverse effects were reported during 15-day supplementation.
- Trial was prospectively registered (IRCT20240903062943N1).
Methodological Strengths
- Randomized, single-blinded, parallel-group design with prospective registration
- Clinically meaningful primary endpoint (time to suture removal) with supportive EWHS
Limitations
- Single-center study with modest sample size
- Single-blinded design without long-term scar outcomes
Future Directions: Conduct multicenter, double-blinded RCTs with longer follow-up including validated scar scales and functional/cosmetic outcomes; explore dose–response and subgroups.
INTRODUCTION: Non-melanoma skin cancers (NMSCs) are the most common malignancies and Mohs micrographic surgery (MMS) with flap reconstruction is the treatment of choice. This study aims to investigate the effect of bromelain on the healing of skin flaps following MMS for NMSCs. METHODS: In a single-center, parallel-group, single-blinded randomized clinical trial, 60 patients with NMSC who underwent MMS and flap reconstruction were assigned (1:1) to either an intervention group receiving bromelain (1500 mg/day, Rataheal™) for 15 days postoperatively or a control group receiving standard care alone. The primary outcome was time to suture removal; the early wound healing score (EWHS) was recorded supportively. Secondary outcomes included pain, inflammation, keloid/scar formation, cosmetic satisfaction, and traction quality. RESULTS: Baseline characteristics (age: 69.2 ± 13.5 years; 71.7% male; flap size: 116.1 ± 7.0 mm CONCLUSION: Bromelain supplementation is associated with earlier postoperative wound healing of skin flaps following MMS for NMSC, leading to 2.6 days earlier suture removal plus improvement in the EWHS without adverse effects. Our findings support the potential of bromelain as a safe and effective adjunct therapy for reconstructive skin cancer surgery. TRIAL REGISTRATION: Iranian Registry of Clinical Trials (IRCT20240903062943N1|| https://irct.behdasht.gov.ir/trial/79056), 2024.10.28, enrollment started after registration.
2. Clinical Efficacy of Titanium-Nickel Shape Memory Alloy Suture for the Repair of Facial Lacerations in Emergency Trauma.
In a randomized comparison of 40 facial laceration patients, deep closure with Ti–Ni shape memory alloy sutures led to fewer complications and better 4-week Vancouver Scar Scale scores than traditional absorbable sutures, with 100% primary healing and higher satisfaction.
Impact: Introduces a tension-stable, removable subcutaneous closure that improves early cosmetic outcomes and reduces complications in facial trauma.
Clinical Implications: For facial trauma, consider Ti–Ni shape memory alloy sutures for deep subcutaneous closure to reduce early complications and improve short-term scarring; ensure appropriate removal at day 14 and assess cost/logistics.
Key Findings
- Randomized trial (n=40) comparing deep subcutaneous closure with Ti–Ni alloy versus absorbable sutures.
- Ti–Ni group achieved 100% primary healing with no infections or suture rejection; control had 10% infection/rejection (P<0.05).
- At 4 weeks, Ti–Ni group had significantly lower VSS subscores (scar widening, erythema, overall impression).
- Patient satisfaction was 100% in Ti–Ni versus 90% in control.
Methodological Strengths
- Randomized controlled comparison with standardized epidermal closure across groups
- Objective scar assessment using Vancouver Scar Scale at predefined time point
Limitations
- Small sample size and single-center study
- Short 4-week follow-up; lack of long-term scar and function outcomes
Future Directions: Larger, multicenter RCTs with longer follow-up (e.g., 6–12 months) including validated scar scales (e.g., POSAS) and cost-effectiveness analyses.
BACKGROUND: To evaluate the clinical efficacy of Titanium-Nickel (Ti-Ni) shape memory alloy sutures in the deep subcutaneous closure of facial emergency lacerations compared with traditional absorbable sutures. METHODS: Forty patients were randomized into a treatment group (n=20, Ti-Ni alloy sutures removed at 14 d) and a control group (n=20, traditional absorbable sutures). Both groups received 7-0 nylon for epidermal closure. Outcomes included wound healing, complication rates (infection/rejection), patient satisfaction, and 4-week Vancouver Scar Scale (VSS) scores. RESULTS: The treatment group achieved a 100% primary healing rate with no infections or suture rejections. In the control group, 10% (2/20) of patients experienced infection and suture rejection (P<0.05). Patient satisfaction was 100% in the treatment group compared with 90% in the control group. At 4 weeks postoperatively, the treatment group demonstrated significantly lower VSS scores for scar widening, erythema, and overall impression than the control group (P<0.05). CONCLUSION: Titanium-nickel (Ti-Ni) memory alloy sutures provide stable tension relief and minimize complications by eliminating long-term subcutaneous foreign bodies. This technique offers a superior alternative for enhancing early cosmetic repair in facial trauma.
3. A rapid single session in vivo method to quantify blue light protection using immediate pigmentation darkening.
This study proposes a single-session in vivo protocol using IPD to quantify blue light protection, yielding a Blue Light Protection Index (BLPI) with a wide dynamic range. Mineral and non-nano filters performed best, and results aligned with a multi-day protocol, supporting this approach for rapid formulation screening and potential standardization.
Impact: Addresses the lack of standardized visible-light protection testing with a reproducible, biologically relevant in vivo method suitable for cosmetic formulation screening.
Clinical Implications: While not a patient-level outcome study, the method can inform product development and claims, aiding dermatologists and consumers in selecting formulations for pigment-prone skin and visible light management.
Key Findings
- Developed a single-session in vivo protocol quantifying blue-light protection via IPD-derived BLPI.
- BLPI spanned 14.6–79.2 (median 34.0), indicating strong discriminatory capacity.
- Mineral and non-nano filters generally outperformed organic-only and nano formulations.
- Good agreement with a multi-day protocol supports external validity for screening.
Methodological Strengths
- In vivo measurement with immediate biological readout (IPD) and reproducibility
- Comparative assessment across formulations with agreement to multi-day reference protocol
Limitations
- Sample size and participant phototypes are not specified in the abstract
- Focus on immediate pigmentation; long-term clinical outcomes not assessed
Future Directions: Standardize test conditions across skin phototypes, validate against clinical endpoints in pigmentary disorders, and develop inter-laboratory harmonization guidelines.
BACKGROUND: Blue light has been implicated in oxidative stress and pigmentary changes, yet no standardized method exists to quantify cosmetic protection in this spectral range. OBJECTIVES: To develop a single session in vivo method that quantifies the protection of topical products against blue light-induced immediate pigmentation darkening (IPD) and to compare its outcomes with a multi-day protocol from the literature. METHODS: IPD was assessed using the Individual Typology Angle (ITA°) measured before (ITA RESULTS: BLPI values ranged from 14.6 to 79.2 (median 34.0), demonstrating a wide dynamic range. Mineral filter formulations predominantly occupied the upper BLPI range, whereas organic-only products were mainly in the lower to intermediate range. Non-nano mineral filters generally outperformed their nano equivalents, and mixed TiO CONCLUSIONS: The proposed single session IPD-based method provides a rapid, reproducible, and biologically relevant assessment of blue light protection. It discriminates effectively between formulations, reflects expected optical behaviour and shows good agreement with a multi-day protocol. This approach is well-suited for formulation screening and could contribute to future methodological harmonization in the visible light domain. CONTEXTE: La lumière bleue est associée au stress oxydatif et à des modifications pigmentaires, mais il n’existe pas de méthode standardisée permettant de quantifier la protection cosmétique dans cette plage spectrale. OBJECTIFS: Développer une méthode in vivo en une seule session permettant de quantifier la protection des produits topiques contre pigmentation immédiate (Immediate Pigmentation Darkening, IPD) induit par la lumière bleue, et comparer ses résultats à ceux d’un protocole sur plusieurs jours décrit dans la littérature. MÉTHODES: L’IPD a été évalué à l’aide de l’Individual Typology Angle (ITA°), mesuré avant (ITA₀) et après exposition (ITA CONCLUSIONS: La méthode proposée, qui s’appuie sur l’IPD et se réalise en une seule session, permet une évaluation rapide, reproductible et biologiquement pertinente de la protection contre la lumière bleue. Elle discrimine efficacement les formulations, reflète le comportement optique attendu et présente une bonne concordance avec un protocole sur plusieurs jours. Cette approche est bien adaptée au criblage des formulations et pourrait contribuer à une future harmonisation méthodologique dans le domaine de la lumière visible.